ONCAlert | 2018 ASCO Annual Meeting

Results from the ASPIRE Trial: Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Shaji Kumar, MD
Published Online: 8:55 PM, Sat December 6, 2014
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.

Clinical Pearls

  • This trial looked at the combination of lenalidomide and dexamethasone with or without carfilzomib for patients with relapsed multiple myeloma.
  • Adding carfilzomib to lenalidomide and dexamethasone elicited an improvement in PFS.
  • The combination was well tolerated.

<<< Go back to the ASH conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.